it has acquired a royalty interest in worldwide sales of Xenpozyme for US$30-million. The company said additional performance-based milestones of up to US$26.5-million could be paid if sales of the drug outperform expectations.
The company said Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency , also known as Niemann-Pick disease. “Xenpozyme is a product that provides ASMD patients and their families with a disease-modifying therapy where none previously existed. The drug represents a transformational shift in therapies available to patients who suffer from ASMD,” said CEO Behzad Khosrowshahi.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: TorontoStar - 🏆 60. / 55 続きを読む »